ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Evaluation of the VITEK
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeMatrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) is integral to routine microbial identification. This study examines the performance of the VITEK® MS PRIME (bioMérieux; "PRIME") system for identification of clinically relevant bacteria, yeasts, and molds.
methodsWe evaluated PRIME using the in vitro diagnostic (IVD) knowledge base version 3.2 (KB3.2) database on 652 clinical isolates, with reference identifications by polymerase chain reaction (PCR) and DNA sequencing. We also compared PRIME results with those obtained using the MALDI Biotyper (Bruker Daltonics; "Biotyper") for bacteria and yeasts in our routine workflow.
resultsPRIME correctly identified 311/317 bacteria (98.1%), 185/196 yeasts (94.4%), and 112/130 molds (86.2%); non-identification for molds was 16/130 (12.3%), with 2/130 (1.5%) misidentifications. Biotyper achieved 308/317 (97.2%) correct identifications for bacteria and 120/196 (61.2%) for yeasts with the IVD database; using the research use only (RUO) database increased the identification rate to 184/196 (93.9%) and reduced non-identifications from 76/196 (38.8%) to 12/196 (6.1%) for yeasts. Misidentifications by PRIME were uncommon, whereas molds-assessed only with PRIME-showed more frequent non-identification and occasional cross-taxon assignments. For example, Fusarium solani was reported as Rhizopus arrhizus, reflecting persistent challenges in MALDI-TOF MS for filamentous fungi and the impact of database breadth. Notably, mold performance observed here lies near the upper range of recent PRIME evaluations using IVD KB3.2.
conclusionsOverall, PRIME provided reliable routine identification for bacteria, yeasts, and molds; further expansion of fungal reference spectra and optimization of extraction workflows should improve mold identification. Pending such improvements, possible non-identifications or discordant assignments should be adjudicated by conventional microbiology before reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.